Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE1, PHASE2

מצבים רפואיים

High Grade Epithelial Ovarian Cancer · High Grade Serous Ovarian Cancer · Primary Peritoneal Carcinoma · Fallopian Tube Cancer · Endometrial Cancer · Non-small Cell Lung Cancer · Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC) · Mesothelioma · Breast Adenocarcinoma · Triple Negative Breast Cancer · Hormone Receptor-positive/Her2 Negative Breast Cancer · Platinum-resistant Ovarian Cancer (PROC) · Platinum Sensitive Ovarian Cancer (PSOC) · Primary Refractory Ovarian Cancer · Uterine Cancer

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • USOR HonorHealth, Phoenix, Arizona, United States

  • USOR Arizona Oncology Associates, Tucson, Arizona, United States

  • University of California Los Angeles Medical Center, Los Angeles, California, United States

  • University of California, San Diego; Moores Cancer Center, San Diego, California, United States

  • USOR Sansum Clinic, Santa Barbara, California, United States

  • Providence Medical Foundation, Santa Rosa, California, United States

  • USOR Florida Cancer Specialists South, Fort Myers, Florida, United States

  • USOR Florida Cancer Specialists North, St. Petersburg, Florida, United States

  • USOR Florida Cancer Specialists East, West Palm Beach, Florida, United States

  • Augusta University Georgia Cancer Center, Augusta, Georgia, United States

  • University of Kansas Medical Center (KUMC), Westwood, Kansas, United States

  • USOR Maryland Oncology Hematology, Rockville, Maryland, United States

  • Massachusetts General Hospital, Boston, Massachusetts, United States

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

  • Karmanos Cancer Institute, Detroit, Michigan, United States

  • START Midwest, Grand Rapids, Michigan, United States

  • USOR Minnesota Oncology Hematology, Maplewood, Minnesota, United States

  • MD Anderson Cancer Center at Cooper- Two Cooper Plaza, Camden, New Jersey, United States

  • Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States

  • University of Oklahoma - Health Sciences Center, Oklahoma City, Oklahoma, United States

  • USOR Oncology Associates of Oregon, P.C., Eugene, Oregon, United States

  • Compass Oncology - Rose Quarter, Portland, Oregon, United States

  • USOR Alliance Cancer Specialist, Doylestown, Pennsylvania, United States

  • Allegheny Health Network, Pittsburgh, Pennsylvania, United States

  • Women and Infants Hospital of Rhode Island, Providence, Rhode Island, United States

  • Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States

  • Tennessee Oncology, Nashville, Tennessee, United States

  • USOR Texas Oncology, Abilene, Texas, United States

  • Texas Oncology - Central / South Texas, Austin, Texas, United States

  • Mary Crowley Cancer Research, Dallas, Texas, United States

  • USOR Texas Oncology, Fort Worth, Texas, United States

  • Texas Oncology - Northeast TX, Tyler, Texas, United States

  • USOR Texas Oncology Gulf Coast, Woodland, Texas, United States

  • START Mountain Region, West Valley City, Utah, United States

  • USOR Virginia Cancer Specialists, Fairfax, Virginia, United States

  • USOR Virginia Oncology Associates, Norfolk, Virginia, United States

  • Swedish Cancer Institute, Seattle, Washington, United States

  • Cancer hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China

  • Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality, China

  • Hunan Cancer Hospital - Phase 1, Changsha, Hunan, China

  • Hunan Cancer Hospital - Thoracic Medicine Dept II, Changsha, Hunan, China

  • Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China

  • Jilin Cancer Hospital, Changchun, Jilin, China

  • Obstetrics & Gynecology Hospital of Fudan University, Chengdu, Shanghai Municipality, China

  • Fudan University Shanghai Cancer Center - Gynecologic Oncology, Shanghai, Shanghai Municipality, China

  • Fudan University Shanghai Cancer Center- Phase 1, Shanghai, Shanghai Municipality, China

  • Shanghai East Hospital, Shanghai, Shanghai Municipality, China

  • Sichuan Cancer Hospital, Shanghai, Sichuan, China

  • Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

  • Fujian Cancer Hospital, Fujian, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong, China

  • Second Affiliated Hospital of Zhengzhou University, Henan, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China

  • Second Hospital of Shanxi Medical University, Shanxi, China

  • Shanxi Cancer Hospital, Shanxi, China

  • Liaoning Cancer Hospital & Institute, Shengyang, China

  • Tianjin Cancer Hospital, Tianjin, China

  • Fukushima Medical University Hospital, Fukushima, Fukushima, Japan

  • Gunma Prefectural Cancer Center, Ōta, Gunma, Japan

  • Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan

  • Hyogo Cancer Center, Akashi, Hyōgo, Japan

  • Saitama Medical University-International Medical Center, Hidaka, Saitama, Japan

  • Shizuoka Cancer Center, Nagaizumi-chō, Shizuoka, Japan

  • Cancer Institute Hospital of JFCR, Koto, Tokyo, Japan

  • Keio University Hospital, Shinjuku-ku, Tokyo, Japan

  • Yamagata University Hospital, Yamagata, Yamagata, Japan

מובילי המחקר
  • Study Official

    Study Director

    Genmab